Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Issues Quarterly Earnings Results

Key Points

• Swedish Orphan Biovitrum reported a quarterly earnings of $0.64 earnings per share (EPS) and a net margin of 16.05%.
• The stock price remained flat at $33.30 with a market capitalization of $11.85 billion.
• Swedish Orphan Biovitrum operates in therapeutic areas such as haematology, immunology, and specialty care, offering several treatments including Alprolix for haemophilia B and Elocta for haemophilia A.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) released its quarterly earnings results on Monday. The company reported $0.64 earnings per share (EPS) for the quarter, Zacks reports. Swedish Orphan Biovitrum had a net margin of 16.05% and a return on equity of 11.67%.

Swedish Orphan Biovitrum Price Performance

BIOVF stock remained flat at $33.30 during trading on Monday. The firm has a market capitalization of $11.85 billion, a PE ratio of 27.98 and a beta of 0.49. Swedish Orphan Biovitrum has a 1-year low of $25.80 and a 1-year high of $33.30. The company's fifty day moving average is $30.47 and its two-hundred day moving average is $29.81. The company has a quick ratio of 0.66, a current ratio of 1.00 and a debt-to-equity ratio of 0.22.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.